Firivumab

立即咨询

Firivumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1443004-15-6

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议

产品名称

CT-P22
CT120

产品介绍

Firivumab (CT-P22; CT120) 是一种人 IgG1 单克隆甲型流感病毒血凝素 (Anti-IAV HA) 抗体。Firivumab 能够中和 H1N1、H5N1、H6N1、H6N2、H8N4、H8N8、H9N2 和 H12N7。Firivumab 在小鼠中显示出对 H1N1 病毒的保护作用。

生物活性

Firivumab (CT-P22; CT120) is a humanIgG1monoclonalinfluenza A virus hemagglutinin (Anti-IAV HA)antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice^[1]^[2]^[3].

IC₅₀& Target

IC50: 0.1-1.3 μg/mL (H1N1), 0.78 μg/mL (H2N2), 0.48-0.65 μg/mL (H5N1), 4.69 μg/mL (H6N1), 4.69 μg/mL (H6N2), 2.34 μg/mL (H8N4), 1.3 μg/mL (H8N8), 2.08 μg/mL (H9N2) and 20.83 μg/mL (H12N7)^[1]

体内研究
(In Vivo)

Firivumab (CT-P22; CT120; 7.5-30 mg/kg; 腹腔给药; 感染后 24 小时) 在 >15 mg/kg 治疗组中对 H1N1 病毒显示 100% 的保护，在 7.5 mg/kg 治疗组中显示 70% 的保护^[1]。
Firivumab (添加 7.5 mg/kg Firivumab 和 7.5 mg/kg CT149) 在 A/California/04/09 (H1N1) 处理的小鼠中表现出全面保护^[1]。

Animal Model:	Six- to nine-week-old female BALB/c mice with A/California/04/09 (H1N1) and A/Philippines/2/1982 (H3N2)^[1]
Dosage:	7.5, 15, 30 mg/kg
Administration:	IP; Twenty-four hours post-infection
Result:	Showed 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group. Could not protect mice from H3N2 infection.

CAS 号

1443004-15-6

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.